These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16178783)

  • 1. Thymidylate synthase structure, function and implication in drug discovery.
    Costi MP; Ferrari S; Venturelli A; Calò S; Tondi D; Barlocco D
    Curr Med Chem; 2005; 12(19):2241-58. PubMed ID: 16178783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate-based thymidylate synthase inhibitors as anticancer drugs.
    Jackman AL; Calvert AH
    Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
    Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.
    Van Triest B; Peters GJ
    Oncology; 1999 Oct; 57(3):179-94. PubMed ID: 10545786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
    Van Triest B; Pinedo HM; Giaccone G; Peters GJ
    Ann Oncol; 2000 Apr; 11(4):385-91. PubMed ID: 10847455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability.
    Kitchens ME; Forsthoefel AM; Barbour KW; Spencer HT; Berger FG
    Mol Pharmacol; 1999 Nov; 56(5):1063-70. PubMed ID: 10531414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
    Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
    Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel chemical strategies for thymidylate synthase inhibition.
    Gmeiner WH
    Curr Med Chem; 2005; 12(2):191-202. PubMed ID: 15638735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.
    Ferrari S; Severi L; Pozzi C; Quotadamo A; Ponterini G; Losi L; Marverti G; Costi MP
    Vitam Horm; 2018; 107():473-513. PubMed ID: 29544641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate-based thymidylate synthase inhibitors in cancer chemotherapy.
    Takemura Y; Jackman AL
    Anticancer Drugs; 1997 Jan; 8(1):3-16. PubMed ID: 9147608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future potential of thymidylate synthase inhibitors in cancer therapy.
    Lehman NL
    Expert Opin Investig Drugs; 2002 Dec; 11(12):1775-87. PubMed ID: 12457437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future challenges in the clinical development of thymidylate synthase inhibitor compounds.
    Brandt DS; Chu E
    Oncol Res; 1997; 9(8):403-10. PubMed ID: 9436193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase inhibition: a structure-based rationale for drug design.
    Costi MP
    Med Res Rev; 1998 Jan; 18(1):21-42. PubMed ID: 9436180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidylate synthase inhibitors.
    Touroutoglou N; Pazdur R
    Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics and ligand-binding preferences of Mycobacterium tuberculosis thymidylate synthases, ThyA and ThyX.
    Hunter JH; Gujjar R; Pang CK; Rathod PK
    PLoS One; 2008 May; 3(5):e2237. PubMed ID: 18493582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
    Banerjee D; Mayer-Kuckuk P; Capiaux G; Budak-Alpdogan T; Gorlick R; Bertino JR
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):164-73. PubMed ID: 12084458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
    Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
    J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.